NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 248 filers reported holding NEKTAR THERAPEUTICS in Q4 2020. The put-call ratio across all filers is 0.43 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $12,230,000 | -52.7% | 3,218,382 | -32.9% | 0.30% | -33.5% |
| Q1 2022 | $25,834,000 | -67.2% | 4,792,920 | -17.7% | 0.45% | -48.9% |
| Q4 2021 | $78,663,000 | -25.0% | 5,822,604 | -0.3% | 0.89% | -15.9% |
| Q3 2021 | $104,858,000 | +6.1% | 5,838,426 | +1.3% | 1.06% | +13.8% |
| Q2 2021 | $98,860,000 | -15.6% | 5,761,073 | -1.7% | 0.93% | -14.0% |
| Q1 2021 | $117,166,000 | +3.6% | 5,858,316 | -12.0% | 1.08% | -40.4% |
| Q4 2020 | $113,146,000 | +20.1% | 6,655,625 | +17.2% | 1.81% | +3.5% |
| Q3 2020 | $94,202,000 | -21.6% | 5,678,221 | +9.5% | 1.75% | -30.7% |
| Q2 2020 | $120,123,000 | +37.4% | 5,186,637 | +5.9% | 2.53% | +36.8% |
| Q1 2020 | $87,436,000 | +25.0% | 4,898,401 | +51.1% | 1.85% | +81.3% |
| Q4 2019 | $69,962,000 | – | 3,241,234 | – | 1.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |